ReviewBiochimica et biophysica acta2016
Histo-blood group glycans in the context of personalized medicine.
Review in Biochimica et biophysica acta, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Edible Plant-Derived Exosome-like Nanoparticles as Prebiotic Nanocarriers: Gut Microbiota Modulation and Functional Food Potential.Pharmaceutics · 2026Review
- Intersections of ABO blood group, secretor status, and the gut microbiome: implications for disease susceptibility and therapeutics.Archives of microbiology · 2025Review
- ABO blood group antigens influence host-microbe interactions and risk of early spontaneous preterm birth.NPJ biofilms and microbiomes · 2025Article
- In Silico Characterization of Glycan Ions from IM-MS Collision Cross Section.Journal of the American Society for Mass Spectrometry · 2025Article
- Assessment of the Relationship Between ABO Blood Group and Familial Cancer Occurrence in Kirkuk City : Relationship Between ABO Blood Group and Familial Cancer Occurrence in Kirkuk City.Galen medical journal · 2025Article
- Human Gb3/CD77 synthase: a glycosyltransferase at the crossroads of immunohematology, toxicology, and cancer research.Cellular & molecular biology letters · 2024Review
- Intestinal persistence of Bifidobacterium infantis is determined by interaction of host genetics and antibiotic exposure.The ISME journal · 2024Article
- Article
- Colon mucus in colorectal neoplasia and beyond.World journal of gastroenterology · 2022Review
- Glycan signatures for the identification of cisplatin-resistant testicular cancer cell lines: Specific glycoprofiling of human chorionic gonadotropin (hCG).Cancer medicine · 2022Article
- Review
- ABO blood group antigen therapy: a potential new strategy against solid tumors.Scientific reports · 2021Article
- Article
- The Potential Contribution of ABO, Lewis and Secretor Histo-Blood Group Carbohydrates in Infection byFrontiers in cellular and infection microbiology · 2021Article
- Colorectal cancer cell lines show striking diversity of their O-glycome reflecting the cellular differentiation phenotype.Cellular and molecular life sciences : CMLS · 2021Article
- Article
- Discovery of Pancreatic Ductal Adenocarcinoma-Related Aberrant Glycosylations: A Multilateral Approach of Lectin Microarray-Based Tissue Glycomic Profiling With Public Transcriptomic Datasets.Frontiers in oncology · 2020Article
- Glycosylation in health and disease.Nature reviews. Nephrology · 2019Review
- N-Glycomic and Transcriptomic Changes Associated with CDX1 mRNA Expression in Colorectal Cancer Cell Lines.Cells · 2019Article
- The Interaction of the Gut Microbiota with the Mucus Barrier in Health and Disease in Human.Microorganisms · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA subset of histo-blood group antigens including ABO and Lewis are oligosaccharide structures which may be conjugated to lipids or proteins. They are known to be important recognition motifs not only in the context of blood transfusions, but also in infection and cancer development. SCOPE OF REVIEW: Current knowledge on the molecular background and the implication of histo-blood group glycans in the prevention and therapy of infectious and non-communicable diseases, such as cancer and cardiovascular disease, is presented. MAJOR
conclusionsGlycan-based histo-blood groups are associated with intestinal microbiota composition, the risk of various diseases as well as therapeutic success of, e.g., vaccination. Their potential as prebiotic or anti-microbial agents, as disease biomarkers and vaccine targets should be further investigated in future studies. For this, recent and future technological advancements will be of particular importance, especially with regard to the unambiguous structural characterization of the glycan portion in combination with information on the protein and lipid carriers of histo-blood group-active glycans in large cohorts. GENERAL SIGNIFICANCE: Histo-blood group glycans have a unique linking position in the complex network of genes, oncodevelopmental biological processes, and disease mechanisms. Thus, they are highly promising targets for novel approaches in the field of personalized medicine. This article is part of a Special Issue entitled "Glycans in personalised medicine" Guest Editor: Professor Gordan Lauc.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.